Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations

Abstract

The overall picture points to an increased risk for neurological complications in association with high levels of biomarkers of BBB disruption. Our observations may provide hints for therapeutic approaches mitigating BBB disruption to reduce the neurological damage in the acute phase and potential dysfunction in the long-term.